Verastem Oncology Entered into a Discovery and Development Collaboration with GenFleet to Advance Three Programs Targeting RAS Pathway-Driven Cancers
Shots:
- GenFleet will receive $11.5M in up front, research & option fees for the initial RAS-targeted program. The deal could total $625.5M excl. royalties, if Verastem exercises the option to in-license 2 other programs
- Verastem gets an exclusive right to obtain a license to each of the compounds after completion of pre-determined milestones in P-I trials & also gets the development & commercialization rights outside of China. GenFleet retains development and commercialization rights inside China
- The collaboration strengthens Verastem’s expertise with GenFleet’s discovery capabilities & enhances GenFleet's global footprint to deliver therapies to cancer patients. The collaboration helps to identify new combination approaches with Verastem lead assets, avutometinib & defactinib
Ref: Businesswire | Image: Verastem
Related News:- Mirati Signs a Non-Exclusive Clinical Collaboration Agreement with Verastem to Evaluate Adagrasib + VS-6766 for KRASG12C-Mutant NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
